Radiation plus chemo for pancreatic cancer pain: trial ends early

NCT ID NCT05114213

Terminated Symptom relief Sponsor: Ludwig-Maximilians - University of Munich Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding MR-guided radiation to standard chemotherapy could reduce pain in people with metastatic pancreatic cancer. Only 9 participants were enrolled before the study was terminated early. The main goal was to track pain scores over time, but the small size and early stop mean no firm conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MR-guided adaptive stereotactic body radiotherapy (SBRT)
What this could lead to: If it worked, this approach could offer better pain control for people with metastatic pancreatic cancer who are already on chemotherapy.
What could go wrong: The trial was terminated early with only 9 participants, so results are very limited. It is unclear if the radiation adds benefit or causes extra side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

University Hospital of Heidelberg, Dep. of Radiation Oncology

Heidelberg, Germany
University Hospital of Zurich

Zurich, Switzerland
University of Munich, Dep. of Radiation Oncology

Munich, Bavaria, 81377, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.